| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||
Research and development revenue | ||||||||
315 | 433 | 454 | 390 | 402 | 686 | 262 | 161 | 184 |
Costs and expenses: | ||||||||
Costs of research and development revenue | ||||||||
278 | 424 | 384 | 322 | 327 | 507 | 243 | 129 | 146 |
Research and development | ||||||||
755 | 735 | 841 | 818 | 692 | 446 | 476 | 601 | 576 |
Research and development - related party | ||||||||
0 | 100 | 100 | 300 | 400 | 159 | 300 | 340 | 400 |
General and administrative | ||||||||
1,653 | 1,164 | 1,056 | 1,870 | 1,428 | 1,284 | 1,023 | 921 | 1,292 |
Foreign currency exchange loss (gain), net | ||||||||
-10 | - | -13 | -4 | -6 | - | -12 | 15 | -4 |
Total costs and expenses | ||||||||
2,697 | 2,369 | 2,397 | 3,352 | 2,843 | 2,452 | 2,044 | 1,977 | 2,414 |
Loss from operations | ||||||||
-2,382 | -1,936 | -1,943 | -2,961 | -2,441 | -1,765 | -1,781 | -1,816 | -2,229 |
Interest income | ||||||||
168 | 207 | 245 | 265 | 266 | 246 | 241 | 219 | 186 |
Loss before income taxes | ||||||||
-2,214 | -1,729 | -1,698 | -2,695 | -2,174 | -1,518 | -1,539 | -1,596 | -2,043 |
Provision for income taxes | ||||||||
0 | 9 | 0 | 0 | 0 | -1,006 | 0 | 0 | 0 |
Net loss | ||||||||
-2,214 | -1,738 | -1,698 | -2,695 | -2,175 | -512 | -1,539 | -1,596 | -2,043 |
Basic and diluted net loss per common share (USD per share) | ||||||||
-0.08 | -0.07 | -0.06 | -0.10 | -0.08 | -0.02 | -0.06 | -0.06 | -0.07 |
Basic and diluted weighted-average common shares outstanding (in shares) | ||||||||
27,452 | 27,291 | 27,181 | 26,828 | 26,713 | 26,698 | 27,774 | 28,060 | 28,159 |